-

08:22:27 AM

STAB Stock News

STAB - Statera BioPharma Inc

03/15/23 8:00 AM

Nasdaq : STAB

acquisition

Statera Biopharma Signs Letter of Intent for Merger with Worksite Labs

Statera Biopharma, Inc. (OTCPK:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, is pleased to announce it has entered into a

RHEA-AI

very positive

01/24/23 9:45 AM

Nasdaq : STAB

Statera Biopharma Announces Completion of Application Process to Uplist to the OTCQB(R) Venture Marketplace

Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, is pleased to announce it has completed the

RHEA-AI

very positive

10/27/22 5:00 PM

Nasdaq : STAB

Statera Biopharma Receives Positive Nasdaq Listing Determination

Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that, by decision dated October

RHEA-AI

neutral

10/21/22 5:42 PM

Nasdaq : STAB

Statera Biopharma Files Form 10-Q and Reaches Agreement with Silverback Capital and AVOF

Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the Company filed its

RHEA-AI

very positive

10/17/22 3:30 PM

Nasdaq : STAB

Statera Biopharma Announces Signing of a Binding MOU with Holobeam Technologies to Gain Access to Holobeam’s Disruptive Diagnostic Imaging and Therapeutic Technology for Cancer Patients

Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced the signing of a binding

RHEA-AI

very positive

10/06/22 6:10 PM

Nasdaq : STAB

earnings

Statera Biopharma Completes Fiscal 2021 Audit; Files Form 10-K

Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the audit of the Company's

RHEA-AI

neutral

09/09/22 7:50 PM

Nasdaq : STAB

Statera Biopharma Receives Nasdaq Listing Determination; Hearing Requested to Address Filing Delinquency

Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced - as disclosed via the Company's

RHEA-AI

neutral

08/25/22 5:30 PM

Nasdaq : STAB

Statera Biopharma Receives Anticipated Notice of Additional Filing Delinquency from Nasdaq

Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that, as expected, the Company

RHEA-AI

neutral

06/14/22 7:30 AM

Nasdaq : STAB

Statera Biopharma Announces BF Borgers CPA PC as Independent Registered Public Accounting Firm

Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced the appointment of

RHEA-AI

neutral

05/23/22 4:05 PM

Nasdaq : STAB

Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-Q Filing

Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced the Company received a letter from the Listing

RHEA-AI

neutral